Despite Hybio Pharmaceutical's recent poor growth, its high P/S ratio indicates investor optimism for a business turnaround. However, with medium-term revenue decline and expected industry growth of 35%, these prices may not be sustainable. Shareholders may face a tough period unless circumstances improve.